AB Science S.A.

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

2026-06-09 12:47:00

PRESS RELEASE AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been linked to a 5-year survival rate of 42.3% from the onset of the disease, marking a two-fold increase compared to historical standards. In patients with ALS who had not experienced a complete loss of functionality, the 5-year survival rate from disease onset rose to 52.9%, underscoring the significance of early intervention.

AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share

2026-06-02 12:05:00

PRESS RELEASE STONEGATE CAPITAL PARTNERS UPDATES ITS COVERAGE OF AB SCIENCE'S STOCK WITH A DISCOUNTED CASH FLOW VALUATION MID-POINT OF EUR 4.25 PER SHARE Paris, June 2 nd , 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that its stock continues to be covered by Stonegate Capital Partners, a leading independent US-based research and investor outreach firm, which has updated its coverage of the stock following the publication of AB Science's full year 2025 results, supported by a discounted cash flow valuation with a mid-point of €4.25 per share (range of €3.20 to €5.77 per share). Stonegate Capital Partners issued this update in a research note entitled “Stonegate Capital Partners Updates Coverage on AB Science S.A.

AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share

2026-05-25 12:06:00

PRESS RELEASE FOLLOWING RELEASE OF FYE2025 RESULTS AND SECURING OF CLINICAL TRIAL INSURANCE POLICY, MAXIM GROUP REITERATES ITS BUY RECOMMENDATION ON AB SCIENCE'S STOCK WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, May 25, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that its stock continues to be covered by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm, which has reiterated its Buy recommendation on the stock with a target price of €4.00 per share. Maxim Group issued this recommendation in a research update entitled “2H25 Review/Outlook: With Masitinib Clinical Trial Insurance Policy Offer, Positioned to Initiate Phase 3 Study for ALS in 2H26”, published on 21 May 2026.

AB Science reports its revenues for the year 2025 and provides an update on its activities

2026-05-13 13:36:00

PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31 December 2025, down 38% compared with the 2025 financial year (excluding non-recurring items) Cash position of €10.2 million as of 31 December 2025, plus €3.2 million from the private placement carried out in April 2026 Final agreement on the renegotiation of the repayment terms of its loans with all financial creditors Clinical development: focus of resources on Phase 3 of masitinib in ALS and Phase 1 of AB8939 in acute myeloid leukaemia (AML) Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its annual financial results as of 31 December 2025 and provides an update on its activities. KEY EVENTS RELATED TO CLINICAL DEVELOPMENT DURING 2025 AND SINCE 31 DECEMBER 2025 In amyotrophic lateral sclerosis (ALS), the masitinib development programme reached several key milestones during 2025 and 2026 i)    Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral sclerosis (ALS) (study AB23005) had been authorised by an initial group of European countries (Spain, Greece, Slovenia) in Stage 2 of the Clinical Trials Information System (CTIS).

AB Science announces the successful completion of a EUR 3.2 million private placement

2026-04-29 02:03:00

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 3.2 MILLION PRIVATE PLACEMENT Paris, April 29, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors (the “Private Placement”).

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

2026-04-27 12:07:00

PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors This agreement provides for a two-year deferral of repayment of the State-Guaranteed Loans and a 12-month deferral of the repayment date of the EIB Covid credit The savings over the period will be invested in R&D Paris, April 27, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt (for a total amount of approximately €3.7 million) and the 12-month deferral of repayment of a loan subscribed with the EIB (for a total principal amount of €12 million, initially repayable in January and December 2028). Throughout the entire negotiation period, a standstill was granted by the creditors.